Study of rifampin and dapsone resistance in three patients with recurring leprosy;Estudio de resistencia a la rifampicina y la dapsona en tres pacientes con recurrencia de lepra

Revista Panamericana de Salud Publica/Pan American Journal of Public Health

Volumn 23, Issue 2, 2008, Pages 73-77

  Hernández, Elkin ^a   Cardona Castro, Nora ^b   Rodríguez, Gerzaín ^a   Villegas, Sonia ^a   Beltrán, Camilo ^b   Kimura, Miyako ^c   Vissa, Varalakshmi D ^c   Gómez, Yenny ^a  

^a UNIVERSIDAD DE LA SABANA   (Colombia)

^b Instituto Colombiano de Medicina Tropical   (Colombia)

^c Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

Colombia; Dapsone; Drug resistance; Leprosy; Mycobacterium leprae; Polymerase chain reaction; Rifampin

Indexed keywords

BACTERIAL DNA; DAPSONE; LEPROSTATIC AGENT; RIFAMPICIN;

ANTIMICROBIAL ACTIVITY; BACTERIUM; DRUG RESISTANCE; LEPROSY; MUTATION;

AGED; ANTIBIOTIC RESISTANCE; ARTICLE; DRUG EFFECT; GENETICS; HUMAN; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RECURRENT DISEASE; RETROSPECTIVE STUDY;

AGED; DAPSONE; DNA, BACTERIAL; DRUG RESISTANCE, MICROBIAL; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MALE; MIDDLE AGED; MYCOBACTERIUM LEPRAE; RECURRENCE; RETROSPECTIVE STUDIES; RIFAMPIN;

MYCOBACTERIUM LEPRAE;

EID: 42149089967     PISSN: 10204989     EISSN: 16805348     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Ji B. Rifampicin resistant leprosy: a review and a research proposal of a pilot study. Lepr Rev. 2002;73:2-8.
2. World Health Organization Study Group. Chemotherapy of leprosy for control programmes. Geneva: WHO; 1982. (WHO Technical Report Series No. 675).
3. Ji B, Perani EG, Petinom C, Grosset JH. Bactericidal activities of combinations of new drugs against Mycobacterium leprae in nude mice. Antimicrob Agents Chemother. 1996;40: 393-9.
4. Ji B, Sow S, Perani E. Bactericidal activities of a single-dose combination of ofloxacin plus minocycline, with or without rifampin, against Mycobacterium leprae in mice and in lepromatous patients. Antimicrob Agents Chemother. 1998;42:1115-20.
5. Lockwood D, Suneetha S. Leprosy: too complex a disease for a simple elimination paradigm. Bull World Health Organ. 2005;83: 230-5.
6. Gelber RH, Balagon MVF, Cellona RV. The relapse rate in MB leprosy patients treated with 2 years of WHO-MDT is not low. Int J Lepr Other Mycobact Dis. 2004;72:493-500.
7. Cellona RV, Balagon MVF, dela Cruz EC, Burgos JA, Abalos RM, Walsh GP, et al. Long-term efficacy of 2-year WHO multiple-drug therapy (MDT) in multibacillary (MB) leprosy patients. Int J Lepr Other Mycobact Dis. 2003; 71:308-19.
8. Kai M, Matsuoka M, Nakata N, Maeda S, Gidoh M, Maeda Y, et al. Diaminodiphenyl-sulfone resistance of Mycobacterium leprae due to mutations in the dihydropteroate synthase gene. FEMS Microbiol Lett. 1999;177: 231-5.
9. You E, Kang T, Kim S, Lee S, Chae G. Mutations in genes related to drug resistance in Mycobacterium leprae isolates from leprosy patients in Korea. J Infect. 2005;50:6-11.
10. Cambau E, Bonnafous P, Perani E, Sougakoff W, Ji B, Jarlier V. Molecular detection of rifampin and ofloxacin resistance for patients who experience relapse of multibacillary leprosy. Clin Infect Dis. 2002;34:39-15.
11. Maeda S, Matsuoka M, Nakata N, Kai M, Maeda Y, Hashimoto K, et al. Multidrug resistant Mycobacterium leprae from patients with leprosy. Antimicrob Agents Chemother. 2001; 45:3635-9.
12. Sekar B, Elangeswaran N, Jayarama E, Rajendran M, Kumar S, Vijayaraghavan R, et al. Drug susceptibility of Mycobacterium leprae: a retrospective analysis of mouse foodpad inoculation results from 1993 to 1997. Lepr Rev. 2002;73:239-44.
13. Dela Cruz E, Cellona R, Balagon M, Villa-hermosa LG, Fajardo TT, Hablaos RM, et al. Primary dapsone resistance in Cebu, the Philippines: cause for concern. Int J Lepr Other Mycobact Dis. 1996;64:264-7.
14. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities (plan period: 2006-2010). Geneva: WHO; 2005. Hallado en: http://www.who.int/lep/resources/ GlobalStrategy.pdf. Acceso el 17 de enero de 2008.
15. Honoré N, Cole ST. Molecular basis of rifampin resistance in Mycobacterium leprae. Antimicrob Agents Chemother. 1993;37:414-8.
16. Williams DL, Spring L, Harris E, Roche P, Gillis TP. Dihydropteroate synthase of Mycobacterium leprae and dapsone resistance. Antimicrob Agents Chemother. 2000;44:1530-7.
17. Rodríguez G, Pinto R, Laverde C, Sarmiento M, Riveros A, Valderrama J, et al. Recidivas postratamiento de la lepra multibacilar. Biomédica. 2004;24:133-9.
18. Torres P, Camarena JJ, Gómez JR, Nogueira JM, Gimeno V, Navarro JC, et al. Comparison of PCR mediated amplification of DNA and the classical methods for detection of Mycobacterium leprae in different types of clinical samples in leprosy patients and contacts. Lepr Rev. 2003;74:18-30.
19. Zhang ZQ, Ishaque M. Evaluation of methods for isolation of DNA from slowly and rapidly growing mycobacteria. Int J Lepr Other Mycobact Dis. 1997;65:469-76.
20. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci. 1977;74:5463-7.
21. Rice P, Longden I, Bleasby A. EMBOSS: the European molecular biology open software suite. Trends Genet. 2000;16:276-7.
22. Telenti A, Imboden P, Marchesi F, Lowrie D, Cole S, Colston MJ, et al. Detection of rifampicin-resistance mutations in Mycobacterium tuberculosis. Lancet. 1993;341:647-50.
23. Jones L, Moszer I, Cole ST. Leproma: a Mycobacterium leprae genome browser. Lepr Rev. 2001;72:470-7.
24. Williams D, Gillis T. Molecular detection of drug resistance in Mycobacterium leprae. Lepr Rev. 2004;75:118-30.
25. Cambau E, Carthagena L, Chauffeur A, Ji B, Jarlier V. Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy. Clin Infect Dis. 2006;42:238-41.
26. Guelpa-Lauras CC, Cartel JL, Constant-Desportes M, Millan J, Bobin P, Guidi C, et al. Primary and secondary dapsone resistance of M. leprae in Martinique, Guadeloupe, New Caledonia, Tahiti, Senegal, and Paris between 1980 and 1985. Int J Lepr Other Mycobact Dis. 1987;55:672-9.
27. Niederweiss M. Mycobacterial porins - new channel proteins in unique outer membranes. Mol Microbiol. 2003;49:1167-77.
28. Li XZ, Zhang L, Nikaido H. Efflux pump-mediated intrinsic drug resistance in Mycobacterium smegma tis. Antimicrob Agents Chemother. 2004;48:2415-23.